These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21395349)

  • 21. Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework?
    Pandya A; Soeteman DI; Gupta A; Kamel H; Mushlin AI; Rosenthal MB
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006492. PubMed ID: 32615799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a Heart Failure Telemonitoring Program Through a Microsimulation Model: Cost-Utility Analysis.
    Boodoo C; Zhang Q; Ross HJ; Alba AC; Laporte A; Seto E
    J Med Internet Res; 2020 Oct; 22(10):e18917. PubMed ID: 33021485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility in medical intensive care patients. Rationalizing ongoing care and timing of discharge from intensive care.
    Thomas K; Peter JV; Christina J; Jagadish AR; Rajan A; Lionel P; Jeyaseelan L; Yadav B; John G; Pichamuthu K; Chacko B; Pari P; Murugesan T; Rajendran K; John A; Sathyendra S; Iyyadurai R; Jasmine S; Karthik R; Mathuram A; Hansdak SG; Abhilash KP; Kumar S; John KR; Sudarsanam TD
    Ann Am Thorac Soc; 2015 Jul; 12(7):1058-65. PubMed ID: 26011090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing image segmentation studies: Statistical power, sample size and reference standard quality.
    Gibson E; Hu Y; Huisman HJ; Barratt DC
    Med Image Anal; 2017 Dec; 42():44-59. PubMed ID: 28772163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A note on the relationship between ex ante and expected willingness to pay for health care.
    Johannesson M
    Soc Sci Med; 1996 Feb; 42(3):305-11. PubMed ID: 8658226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.
    Goodacre S; Sampson F; Stevenson M; Wailoo A; Sutton A; Thomas S; Locker T; Ryan A
    Health Technol Assess; 2006 May; 10(15):1-168, iii-iv. PubMed ID: 16707072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis when the WTA is greater than the WTP.
    Willan AR; O'Brien BJ; Leyva RA
    Stat Med; 2001 Nov; 20(21):3251-9. PubMed ID: 11746316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A note on confidence intervals in cost-effectiveness analysis.
    Tambour M; Zethraeus N; Johannesson M
    Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of outliers on confidence interval procedures for cost-effectiveness ratios.
    Indurkhya A; Gardiner JC; Luo Z
    Stat Med; 2001 May 15-30; 20(9-10):1469-77. PubMed ID: 11343367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment.
    Wolff E; Larsson S; Svensson M
    Value Health; 2020 Oct; 23(10):1384-1390. PubMed ID: 33032783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.
    Shih YC; Pan IW; Tsai YW
    Pharmacoeconomics; 2009; 27(11):947-61. PubMed ID: 19888794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unintended consequences of applying economic evaluation.
    Oliver A
    J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessing preferences for prevention versus treatment using willingness to pay.
    Corso PS; Hammitt JK; Graham JD; Dicker RC; Goldie SJ
    Med Decis Making; 2002; 22(5 Suppl):S92-101. PubMed ID: 12369235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Willingness to pay as a measure of health benefits.
    Bala MV; Mauskopf JA; Wood LL
    Pharmacoeconomics; 1999 Jan; 15(1):9-18. PubMed ID: 10345161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.
    de Verteuil R; Imamura M; Zhu S; Glazener C; Fraser C; Munro N; Hutchison J; Grant A; Coyle D; Coyle K; Vale L
    Health Technol Assess; 2008 Jun; 12(26):iii-iv, ix-223. PubMed ID: 18513467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confidence intervals for cost-effectiveness ratios.
    Gardiner J; Hogan A; Holmes-Rovner M; Rovner D; Griffith L; Kupersmith J
    Med Decis Making; 1995; 15(3):254-63. PubMed ID: 7564939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.